Despite the evidence favoring this new paradigm of complement anaphylatoxin-supported tumor progression under defined experimental conditions, it is premature to infer that targeting C3aR and C5aR would be an appropriate adjuvant antitumor strategy. This evidence concerns the gene C5AR1 and neoplasm.